William D. Collins

• Kymera Therapeutics in connection with its $30 million Series A financing, $65 million Series B financing and its $102 million Series C financing, its strategic collaborations with Vertex Pharmaceuticals and Sanofi, its $200 million initial public offering, its $150 million PIPE, and its $200 million,  $275 million and $700 million follow-on public offerings.
• Upstream Bio with its $200 million Series B financing and $293 million initial public offering
• Nimbus Therapeutics in connection with its $1.2 billion sale of its ACC inhibitor program to Gilead Biosciences, its $60 million financing, $105 million financing, $125 million financing completed since 2020, and its $6 billion sale of its TYK2 inhibitor to Takeda Pharmaceuticals
• Dren Bio in connect with its sale of DR-0201 to Sanofi for up to $1.9 billion and related corporate restructuring
• Sionna Therapeutics in its $111 million Series B financing, $182 Series C financing and $191 million IPO
• Disc Medicine in connection with its $50 million Series A financing, its $90 million Series B financing, its reverse merger transaction with Gemini Therapeutics, and $335 million in registered equity financings
• Relay Therapeutics in connection with its $57 million Series A financing, its $63 million Series B financing and its $400 million Series C financing, its $460 million initial public offering, and multiple follow-on offerings of more than $330 million, and its $85 million acquisition of ZebiAI
• Triveni Bio in its $92 million Series A financing and $115 million Series B financing 
• Forma Therapeutics in connection with its $100 million Series D financing, its $319.3 million initial public offering, its $275.8 million follow-on public offering, its $200 million “at-the-market” offering, and its $1.1 billion sale to Novo Nordisk
• Myeloid Therapeutics in its $73 million financingROME Therapeutics in its $50 million Series A financing and $77 million Series B financing
• Obsidian Therapeutics in connection with its $49.5 million Series A financing, $115 million Series B financing, and $160 million Series C financing 
• Orionis Biosciences in its research collaboration and financing transactions with various large pharmas
• Nvelop Therapeutics in its $100 million financing and merger with Chroma Medicine 
• Accent Therapeutics in its $63.5 million Series B financing and Series C financing
• Oak Hill Bio on a variety of financing and strategic transactions
• EQRx in connection with its $200 million Series A financing and $500 million Series B Financing, its $5.35 billion business combination with CM Life Sciences III, including its $1.2 billion PIPE financing, and its sale to Revolution Medicines
• Tango Therapeutics in connection with its $55 million Series A financing and its $60 million Series B financing, its $1.0 billion definitive business combination with BCTG Acquisition Corp and its $80 million PIPE financing 
• HotSpot Therapeutics, Inc. in its $100 million Series C financing
• Magenta Therapeutics in connection with its $48.5 million Series A financing and its $50 million Series B financing, its $100 million initial public offering and its reverse merger with Dianthus Therapeutics
• Intellia Therapeutics in connection with its foundational license agreement with Caribou Biosciences pursuant to which Intellia has the right to therapeutic applications of CRISPR/Cas9 technology, its collaboration and license agreements with Novartis and Regeneron, its $124.2 million initial public offering, and its $150 million follow-on public offering
• Ikena Oncology in connection with its $120 million Series B financing and its $143.8 million initial public offering

• The underwriters in connection with Metsera’s $275 million initial public offering
• TScan Therapeutics in multiple equity financings
• Rocket Pharmaceuticals in its $299 million and $100 million follow-on financings
• Candel Therapeutics in its $72 million initial public offering and $80 million registered equity offering
• Praxis Precision Medicines in its $104.9 million underwritten public offering 
• TCR2 Therapeutics in its $75 million underwritten public offering 
• Bluebird bio in its $116.1 million initial public offering
• Other clinical stage and commercial stage issuers in more than $10 billion in equity and debt offerings

• IDRX in its sale of GSK
• Thrive Earlier Detection Corp. in connection with its $2.15 billion sale to Exact Sciences Corporation
• Rodin Therapeutics in its $950 million sale to Alkermes
• Padlock Therapeutics in its $600 million sale to Bristol-Meyers Squibb
• Celsius Therapeutics in its $250 million sale to AbbVie
• ARKUDA Therapeutics in its transaction with Johnson and Johnson 
• Ocata Therapeutics in its sale to Astellas
• Albany Molecular Research Inc. in its sale to The Carlyle Group and GTCR
• Outcome Sciences in its sale to Quintiles Transnational (NASDAQ: Q)
• ZOLL Medical in its acquisition of Kyma Medical Systems and other business development transactions

Bill also represents leading life science venture capital and investment firms, including Atlas Venture, Bain Capital Life Sciences, Third Rock Ventures, Curie Bio, Population Health Partners, ARCH Venture Partners, Newpath Partners, Lightstone Ventures and others, in connection with their portfolio investments and related matters.